Prothena (PRTA)
(Delayed Data from NSDQ)
$24.13 USD
+1.54 (6.82%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $24.44 +0.31 (1.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 321 - 335 ( 335 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Analyst Day Takeaways: Significant Opportunity in Next Two Clinical Candidates Overlooked - Next Up,
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Increasing Price Target to $32 - Nov. 4 Analyst Day to Highlight Clinical Path Forward in Amyloidosis
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
We launch coverage with a Buy and a $16 target.
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R